| Boston Scientific Corp (BSX) | |||
|---|---|---|---|
| 47.8 0.85 (1.81%) | 09-04 16:00 | ||
| Open: | 46.87 | Pre. Close: | 46.95 |
| High: | 48.0583 | Low: | 46.85 |
| Volume: | 15,438,005 | Market Cap: | 71,048(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 58.82  One year: 61.89 |
| Support: | Support1: 46.10 Support2: 38.36 |
| Resistance: | Resistance1: 50.36 Resistance2: 52.99 |
| Pivot: | 48.91  |
| Moving Averages: | MA(5): 47.90 MA(20): 49.51 MA(100): 50.19 MA(250): 73.33 |
| MACD: | MACD(12,26): -0.07 Signal(12,26,9): 0.31 |
| %K %D: | %K(14,3): 23.84 %D(3): 26.54 |
| RSI: | RSI(14): 47.74 |
| 52-Week: | High: 109.5 Low: 42.2 Change(%): -55.8 |
| Average Vol(K): | 3-Month: 19764 10-Days: 18900 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 48.105 - 48.338 | 48.338 - 48.539 |
| Low: | 46.294 - 46.562 | 46.562 - 46.794 |
| Close: | 47.405 - 47.824 | 47.824 - 48.186 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BSX ] has closed above bottom band by 32.6%. Bollinger Bands are 19.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Medical - Devices | |
| Shares Out. (M) | 1450.00 |
| Shares Float (M) | 1440.00 |
| % Held by Insiders | 0.25 |
| % Held by Institutions | 95.37 |
| Shares Short (K) | 22280 |
| Shares Short Prior Month (K) | 27940 |
| Stock Financials | |
|---|---|
| EPS | 2.470 |
| Book Value (p.s.) | 17.230 |
| Profit Margin | 17.50 |
| Operating Margin | 22.90 |
| Return on Assets (ttm) | 6.2 |
| Return on Equity (ttm) | 15.3 |
| Qtrly Rev. Growth | 7.5 |
| Gross Profit (p.s.) | 10.021 |
| Sales Per Share | 14.483 |
| EBITDA (p.s.) | 3.938 |
| Qtrly Earnings Growth | 15.10 |
| Operating Cash Flow (M) | 4530.00 |
| Levered Free Cash Flow (M) | 2450.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 19.35 |
| PEG Ratio | 0.72 |
| Price to Book value | 2.77 |
| Price to Sales | 3.30 |
| Price to Cash Flow | 15.30 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
